The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

$97M Settlement Between Gilead and DOJ Over Kickbacks

Posted on September 25, 2020 by The National Trial Lawyers

Amid an industrywide kickbacks investigation into pharma’s charity contributions, Gilead Sciences has become the latest drugmaker to strike a deal. Though the company says it doesn’t believe it violated any laws, it agreed to pay $97 million to resolve kickbacks allegations.

Gilead inked the settlement with the Department of Justice (DOJ) to resolve claims it used a patient foundation as a “conduit” to cover Medicare patients’ copays for Letairis, a pulmonary arterial hypertension drug that’s now off patent.

Gilead is the latest drugmaker to strike a deal in the yearslong probe, following settlements of various sizes for Sanofi, Pfizer, Astellas, Amgen, Alexion and United Therapeutics, among others. 

Read the source article at Pharma News

Posted in Civil Plaintiff

Comments are closed.

Recent Posts

Geico Workers Allege Tactics to Prevent Union

Geico Workers Allege Tactics to Prevent Union

September 30th, 2022

Workers at an office of US insurance giant Geico have embarked on a unionization campaign in the face of what they say are a[Read More...]
Walgreens Sued for Pregnancy Discrimination

Walgreens Sued for Pregnancy Discrimination

September 30th, 2022

Walgreens is facing a federal lawsuit after a store manager refused to let a pregnant worker leave and see her doctor after [Read More...]
Man Files $100M Lawsuit Over Injuries Suffered in Police Van

Man Files $100M Lawsuit Over Injuries Suffered in Police Van

September 28th, 2022

Lawyers for Randy Cox, a Black man who was paralyzed from the chest down in June when a police van without seat belts braked[Read More...]
Biogen Settles Allegations of Doctor Kickbacks for $900M

Biogen Settles Allegations of Doctor Kickbacks for $900M

September 28th, 2022

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to [Read More...]
What To Know About Workers' Compensation

What To Know About Workers' Compensation

September 27th, 2022

There is always a potential that you might be in an unavoidable position where an accident can happen, regardless of how[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.